CAR-T Meeting 2024 | Enhancing outcomes of patients with DLBCL treated with CAR T-cell therapy
Stefania Bramanti
• 17 Feb 2024
In this video, Stefania Bramanti, MD, Humanitas Research Hospital, Rozzano, Italy, briefly discusses how CAR T-cell therapy outcomes can be improved in patients with diffuse large B-cell lymphoma (DLBCL). Administering CAR-T in patients who have received fewer prior lines of therapy will likely enhance efficacy and minimize toxicity. Dr Bramanti highlights that patients selection for CAR-T should involved stratification based on molecular prognostic factors. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
